• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Regencell Bioscience Holdings Limited

    12/15/21 9:48:09 AM ET
    $RGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RGC alert in real time by email
    SC 13G 1 ea152201-13gdigital_regen.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Regencell Bioscience Holdings Limited

    (Name of Issuer)

     

    Ordinary Shares, $0.00001 Par Value

    (Title of Class of Securities)

     

    G7487R100

    (CUSIP Number)

     

    July 16, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(b)

     

    ☐Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G7487R100   Page 2 of 7

     

    1.

    Names of Reporting Persons.

    Digital Mobile Ventures, Ltd.

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    British Virgin Island

    Number of Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    988,902*

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    988,902*

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    988,902

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

    7.63%**

    12.

    Type of Reporting Person

    CO

     

    *Represents ordinary shares held as of December 10, 2021 by Digital Mobile Venture Ltd.

     

    **Percentage of class based on 12,967,105 ordinary shares outstanding as of December 10, 2021, which information was provided by the Issuer to the Reporting Persons on December 10, 2021.

     

     

     

     

    CUSIP No. G7487R100   Page 3 of 7

     

    1.

    Names of Reporting Persons

    Samuel Chen

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Taiwan

    Number of Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    988,902*

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    988,902*

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    988,902

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

    7.63%**

    12.

    Type of Reporting Person

    IN

     

    *Represents ordinary shares indirectly held as of December 10, 2021 Samuel Chen via Digital Mobile Venture Ltd.

     

    **Percentage of class based on 12,967,105 ordinary shares outstanding as of December 10, 2021, which information was provided by the Issuer to the Reporting Persons on December 10, 2021.

     

     

     

     

    CUSIP No. G7487R100   Page 4 of 7

     

    1.

    Names of Reporting Persons

    Fiona Chang

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Taiwan

    Number of Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    988,902

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    988,902

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    0

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

    11.

    Percent of Class Represented by Amount in Row (9)

    7.63%**

    12.

    Type of Reporting Person

    IN

     

    *Represents ordinary shares indirectly held as of December 10, 2021 by Fiona Chang via Digital Mobile Venture Ltd.

     

    **Percentage of class based on 12,967,105 ordinary shares outstanding as of December 10, 2021, which information was provided by the Issuer to the Reporting Persons on December 10, 2021.

     

     

     

     

    CUSIP No. G7487R100   Page 5 of 7

     

    ITEM 1.

     

    (a) Name of Issuer: Regencell Bioscience Holdings Limited

     

    (b) Address of Issuer’s Principal Executive Offices: 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong

     

    ITEM 2.

     

    (a) Name of Persons Filing:

     

    Digital Mobile Ventures Ltd., a British Virgin Islands company (“Digital Mobile”).

     

    Samuel Chen and Fiona Chang, who are directors and stockholders of Digital Mobile (the individuals referred to above are collectively referred to herein as the “Managers”).

     

    (b) Address of Principal Business Office, or if None, Residence:

     

    The Business Address of Digital and the Managers is c/o Rayson Technology Co. Ltd., 5F, No. 550, Ruei Guang Road, Taipei, Taiwan

     

    (c) Citizenship:

     

    Digital Mobile is a British Virgin Islands company and the Managers are citizens of Taiwan.

     

    (d) Title of Class of Securities: Ordinary Share

     

    (e) CUSIP Number: G7487R100

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    ITEM 4. OWNERSHIP.

     

    The information requested in these paragraphs is incorporated herein by reference to the cover pages to this Schedule 13G.

     

     

     

     

    CUSIP No. G7487R100   Page 6 of 7

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    Not applicable.

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10. CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    EXHIBIT INDEX

     

    Exhibit Joint Filing Agreement, dated December 15, 2021. 

     

     

     

     

    CUSIP No. G7487R100   Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      December 15, 2021
       
      Digital Mobile Ventures, Ltd.
         
      By: /s/ Samuel Chen
      Name:  Samuel Chen
      Title: Chairman of the Board
         
      By: /s/ Samuel Chen
      Name: Samuel Chen
         
      By: /s/ Fiona Chang
      Name: Fiona Chang

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

     

     

     

    Get the next $RGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

      - The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD ("SKATBT-A3"), which measures the effectiveness of the treatment on the patient's overall body and neurodevelopmental conditions, showed a mean percentage improvement of 37% in the second efficacy trial based on the scoring system of SKATBT-A3. - The first efficacy trial using personalized TCM formulae have shown a mean percentage improvement of 30% in ADHD symptoms and a mean percentage improvement of 37% in ASD symptoms, based on the scoring systems under the Vanderbilt ADHD Diagnostic Parent Rating Scale ("VADRS") and the Autism Treatment Evaluation Checklist ("ATEC"), respectively, after 3 months of treatment. - The ongoin

      9/12/22 9:15:00 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

      Regencell Bioscience Holdings Limited (NASDAQ:RGC): Results of EARTH efficacy trial   EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19TM (% of patients) 90.2 83.8 87.5 Testing negative in 6 days (% of patients) 23.5 43.5 29.7 Recovery period for patients who took RGC-COV19TM within 3 days of sy

      5/18/22 8:05:00 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

      Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that Yat-Gai Au, the Company's Chairman and CEO, made purchases of ordinary shares in Regencell ("Ordinary Shares") totaling $5.03 million. Based on his Schedule 13D filings with the U.S. Securities and Exchange Commission (the "SEC") between July 27, 2021 and May 16, 2022, Mr. Au used an aggregate of $5.03 million of his personal funds to

      5/16/22 7:00:00 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $RGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Regencell Bioscience Holdings Limited (Amendment)

      SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

      7/26/22 8:34:12 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Regencell Bioscience Holdings Limited (Amendment)

      SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

      5/16/22 6:15:44 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Regencell Bioscience Holdings Limited (Amendment)

      SC 13D/A - Regencell Bioscience Holdings Ltd (0001829667) (Subject)

      4/4/22 7:30:24 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $RGC
    SEC Filings

    See more
    • SEC Form 6-K filed by Regencell Bioscience Holdings Limited

      6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

      1/15/25 6:02:56 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 20-F filed by Regencell Bioscience Holdings Limited

      20-F - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

      10/25/24 4:15:27 PM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Regencell Bioscience Holdings Limited

      6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)

      6/20/24 9:13:05 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $RGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

      Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the vacancy resulting from the resignation of a former director in November of this year. Dr. Lo will act as the chairperson of the audit committee and the member of the compensation committee and the nomination and corporate governan

      12/13/21 8:35:00 AM ET
      $RGC
      Medicinal Chemicals and Botanical Products
      Health Care